Navigation Links
Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer

SEATTLE, Dec. 2, 2011 /PRNewswire/ -- Immune Design Corp. announced today that Wayne R. Gombotz, Ph.D. has joined the company as its new Chief Development Officer.  Dr. Gombotz brings a significant amount of product development experience to this key leadership position at Immune Design.  He will oversee product development and manufacturing for Immune Design's therapeutic vaccine product candidates.


Wayne R. Gombotz, Ph.D., most recently served as Vice President of Pharmaceutical Operations at Omeros Corporation from 2005 to 2011. He was responsible for product development and manufacturing for Omeros' pharmaceutical and biopharmaceutical technology platforms.  Prior to this, from 2002 to 2005, Dr. Gombotz was Vice President of Process Science and Pharmaceutical Development at Corixa Corporation.  During the three years he spent at Corixa, he built and led a team that championed immunotherapeutic products.  Corixa was acquired by GlaxoSmithKline plc in 2005.  Prior to joining Corixa, Dr. Gombotz served as a Senior Director of Analytical Chemistry and Formulation at Amgen (formerly Immunex) from 1995 to 2002 where he played a major role in the development and launch of ENBREL®.  He has 25 years of experience providing technical and administrative direction of clinical and commercial manufacturing operations, process development, and process validation functions.  Dr. Gombotz received Ph.D. and M.S. in bioengineering from the University of Washington, Seattle, WA, and received his B.A. in biology from Colby College, Waterville, ME.

"Wayne brings an exceptional and seasoned skill set to Immune Design with very unique capabilities," stated Carlos V. Paya, M.D., Ph.D., President and Chief Executive Officer. "As we looked to expand our leadership team, we sought someone who we believed would bring a unique viewpoint to our research team and be capable of applying that vision to the multidimensional challenge of vaccine discovery and development.  Wayne is exactly that kind of leader."

Dr. Gombotz commented, "I am excited about the opportunity to join Immune Design.  The company has several key technology platforms that provide it with the potential to become a major player in the development of novel vaccines."

About Immune Design Corp.

Immune Design is a privately held, clinical-stage biotechnology company based in Seattle, Washington, and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease.  The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response.  This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms.

Additional information can be found on the company's website at

Contact Media:

Cassie Ostrander 206-826-7901 or



SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... relationship marketing company specializing in scientifically backed, age-defying products, is featured as ... which highlights the exponential success and unrivaled opportunities that Nerium provides. Success ...
(Date:12/1/2015)... Dallas, Texas (PRWEB) , ... December 01, 2015 ... ... its annual global meeting this month and Dr. J. Kyle Mathews ... worldwide.” This includes the new single site hysterectomy. , An experienced urogynecologist, founder ...
(Date:11/30/2015)... ... , ... Global Stem Cells Group announced that its scientific team ... isolating adipose-derived stem cells. The announcement starts a new phase toward launching the simple, ... component of the lipoaspirate obtained from liposuction of excess adipose tissue. , Lipoaspirate, ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
Breaking Biology Technology:
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
Breaking Biology News(10 mins):